By Sneha S K and Puyaan Singh (Reuters) -Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's ...

Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lilly's diabetes and weight-loss drugs on its platform ...

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ...

Combination treatment with a GLP-1 agonist and thiazolidinedione in type 2 diabetes was tied to a significantly lower risk of ...

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...

Por THE ASSOCIATED PRESSUna comisión reguladora europea rechazó el tratamiento de Eli Lilly contra la enfermedad de Alzheimer ...

As the women’s NCAA March Madness tournament draws to a close, Eli Lilly is aiming for a slam dunk of its own. | As the women ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...